# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL			
OMB Number:	3235-02		

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response													
1. Name and Address of Reporting Person * RINGROSE PETER S				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)X Director 10% Owner				
(Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/29/2009						Officer (giv	e title below)	Oth	ner (specify below)	)
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)					_X_1	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(City	(City) (State) (Zip)			Table I - Non-Derivative Securities Acqu					es Acquired,	lired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Ye			2A. Deemed Execution Date any (Month/Day/Ye			(/	Securities Acq A) or Disposed onstr. 3, 4 and 5)	of (D) Own Tran			d	Ownership Form: B Direct (D) O	Beneficial Ownership	
						Cod	le V A	mount (A) or	Price	Ca			or Indirect (Instr (I) (Instr. 4)	nstr. 4)
Reminder:	Report on a s	separate line for each	i class of securities t	beneficial	iy owned d	псену	Person in this f	s who respon form are not r s a currently	equired to	respond	unless the		ned SEC 14	174 (9-02)
Reminder:	Report on a s	separate line for each	class of securities t	benenciai	iy owned d	пссиу	Person in this f	s who respon	equired to	respond	unless the		ned SEC 14	174 (9-02)
1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction	Table II -  3A. Deemed Execution Date, if any	Derivativ (e.g., put 4. Transact Code	ve Securiti s, calls, wa 5. Nur ion of Der Securi	es Acq errants nber ivative ties	Persons in this f display uired, Dispos, options, co	s who respondered from are not respondered from the second fro	equired to valid OMB eficially Own ities)  7. Title and of Underlying Securities	respond control r ned I Amount ing	unless the	9. Number of Derivative Securities	of 10. Ownership Form of	11. Natu p of Indire Benefici
1. Title of Derivative Security	2. Conversion	3. Transaction	Table II -  3A. Deemed Execution Date, if	Derivativ (e.g., put 4. Transact Code	ve Securiti s, calls, wa 5. Nur ion of Der Securi	es Acq rrants nber ivative ties red (A) posed	Personin this fidisplay uired, Disponoutions, co  6. Date Exe Expiration	s who respondered from are not respondered from the second fro	equired to valid OMB eficially Own ities)  7. Title and of Underlyi	respond control r ned Amount ing d 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	of 10. Ownership Form of Derivative Security: Direct (D) or Indirect (s) (I)	11. Natu p of Indire Benefici Ownersh (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction	Table II -  3A. Deemed Execution Date, if any	Derivativ (e.g., put 4. Transact Code	ve Securiti s, calls, wa of Der Securi Acqui or Dis of (D) (Instr.	es Acq rrants nber ivative ties red (A) posed	Personin this fidisplay uired, Disponoutions, co  6. Date Exe Expiration	s who resported are not responsed of, or Benevitible securicisable and Date y/Year)	equired to valid OMB eficially Own ities)  7. Title and of Underlying Securities	respond control r ned I Amount ing	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported	Of Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indire Benefici Ownersi (Instr. 4)

### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
RINGROSE PETER S RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X					

# **Signatures**

/s/ Dolly Vance (Attorney-in-Fact)	05/29/2009
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly over twelve (12) months from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.